Cover Image
市場調查報告書

毛細胞白血病:開發中產品分析

Hairy Cell Leukemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253659
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
毛細胞白血病:開發中產品分析 Hairy Cell Leukemia - Pipeline Review, H2 2016
出版日期: 2016年10月30日 內容資訊: 英文 93 Pages
簡介

毛細胞白血病,是呈現緩慢過程,稀少的血液癌症,骨髓會製造過許多B細胞(淋巴球)。症狀有疲勞、容易出現瘀血、感染疾病復發、虛弱、體重減少等。危險因素,包含放射線、化學物質的暴露等。治療有外科手術、化療、放射線治療等。

對本報告提供毛細胞白血病的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

毛細胞白血病概要

治療藥的開發

  • 開發中產品的概要

毛細胞白血病:企業開發中的治療藥

毛細胞白血病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

毛細胞白血病:企業開發中的產品

毛細胞白血病的治療藥的開發企業

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biogenomics Limited
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Juno Therapeutics Inc.
  • MedImmune, LLC
  • Novartis AG

毛細胞白血病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

毛細胞白血病:最近的開發平台趨勢

毛細胞白血病:暫停中的計劃

毛細胞白血病:開發中止的產品

毛細胞白血病:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8630IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2016, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 1, 1, 2 and 1 respectively.Hairy Cell Leukemia.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Hairy Cell Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for Hairy Cell Leukemia - Overview
  • Hairy Cell Leukemia - Therapeutics under Development by Companies
  • Hairy Cell Leukemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hairy Cell Leukemia - Products under Development by Companies
  • Hairy Cell Leukemia - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • ARA Healthcare Pvt. Ltd.
    • Astellas Pharma Inc.
    • Biogenomics Limited
    • F. Hoffmann-La Roche Ltd.
    • Incyte Corporation
    • Juno Therapeutics Inc.
    • MedImmune LLC
    • Novartis AG
  • Hairy Cell Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dezapelisib + itacitinib adipate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGS-67E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARABS-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dezapelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-50465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCAR-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • moxetumomab pasudotox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vemurafenib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hairy Cell Leukemia - Dormant Projects
  • Hairy Cell Leukemia - Discontinued Products
  • Hairy Cell Leukemia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumors
      • May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hairy Cell Leukemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hairy Cell Leukemia - Pipeline by AbbVie Inc, H2 2016
  • Hairy Cell Leukemia - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
  • Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2016
  • Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H2 2016
  • Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Hairy Cell Leukemia - Pipeline by Incyte Corporation, H2 2016
  • Hairy Cell Leukemia - Pipeline by Juno Therapeutics Inc., H2 2016
  • Hairy Cell Leukemia - Pipeline by MedImmune LLC, H2 2016
  • Hairy Cell Leukemia - Pipeline by Novartis AG, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hairy Cell Leukemia - Dormant Projects, H2 2016
  • Hairy Cell Leukemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hairy Cell Leukemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top